Lavoisier S.A.S.
14 rue de Provigny
94236 Cachan cedex
FRANCE

Heures d'ouverture 08h30-12h30/13h30-17h30
Tél.: +33 (0)1 47 40 67 00
Fax: +33 (0)1 47 40 67 02


Url canonique : www.lavoisier.fr/livre/autre/management-of-bladder-cancer/konety/descriptif_3076594
Url courte ou permalien : www.lavoisier.fr/livre/notice.asp?ouvrage=3076594

Management of Bladder Cancer, Softcover reprint of the original 1st ed. 2015 A Comprehensive Text With Clinical Scenarios

Langue : Anglais
Couverture de l’ouvrage Management of Bladder Cancer

Management of bladder cancer provides a single, comprehensive reference source that incorporates all the latest information regarding bladder cancer. The text covers epidemiology and natural history of bladder cancer as well as latest findings regarding the genetics and molecular biology of the disease. Diagnostic and staging evaluation of both non-muscle invasive and invasive bladder cancer is discussed. The text incorporates chapters summarizing new findings regarding markers for the diagnosis of bladder cancer and new diagnostic techniques to enhance traditional methods such as cystoscopy. Risk stratified treatment of non muscle invasive bladder cancer including various approaches to intravesical therapy are reviewed. Current guideline based approaches to management and new data regarding diagnosis and prognostication of muscle invasive bladder cancer is analyzed and summarized. The application of chemotherapy for muscle invasive and advanced disease is discussed and the evidence based application of multimodality therapy highlighted. Finally, gaps in current knowledge and areas for future research are highlighted. Ongoing important clinical trials which could imminently yield significant new knowledge is discussed.

Authored by experts in their respective fields, Management of Bladder Cancer will serve as a easy and complete reference source for clinicians, researchers, individuals in training, allied health professionals and medical students in the fields of Urology, Medical Oncology, Radiation Oncology, Basic and Translational Science and Epidemiology.

Epidemiology and natural history.- Screening for Bladder Cancer.- Pathology and Staging: Histopathology and Cytopathology.- Pathology and Staging: Genetics and Molecular Biology.- Imaging in Localized and Advanced Bladder Cancer.- New Imaging Techniques in Staging of Urothelial Carcinoma of the Bladder.- Socioeconomic issues and improved quality of care.- Quality of life measures.- Prognostication and risk assessment.- Clinical trials and emerging therapeutic strategies in bladder cancer.- Improved diagnostic techniques.- Clinical scenario: Microscopic hematuria and atypical cytology in a 68 year old man with normal upper tract imaging.- Localized surgical therapy and surveillance.- Clinical Scenario: Initial high grade Ta tumor.- Clinical Scenario: Recurrent Ta tumor.- Clinical Scenario: Rapidly growing, high volume, low grade Ta tumor.- Clinical Scenario: Low grade T1 tumor.- Intravesical therapy.- Clinical Scenario: Initial CIS.- Management of BCG Recurrent Bladder Cancer.- Clinical Scenario: Persistent CIS and HIGH Grade Ta Bladder Cancer after BCG.- Maurizio Brausi.- Clinical Scenario: Presentation and Management of Significant Side Effects from Bacillus Calmette-Guérin Bladder Instillation.- Guideline-based management of non-muscle invasive bladder cancer: comparison of the AUA, EAU, ICUD and NCCN guidelines.- Open Radical Cystectomy.- Robotic cystectomy.- Clinical Scenario: T2 bladder tumor.- Urinary Diversion: Open and robotic techniques.- Chemoradiotherapy.- Clinical Scenario: 53 year-old man with a solitary, 2 cm, high-grade T2 tumor and focal CIS in the bladder dome who wants bladder preservation.- Management of Bladder Cancer, role of chemotherapy and controversies surrounding its application.- Clinical Scenario: Large volume, non metastatic T2 bladder tumor.- The role of pelvic lymphadenectomy at the time of radical cystectomy for bladder cancer.- Clinical Scenario: Unexpected positive nodes at radical cystectomy.- Surveillance andmonitoring.- Clinical Scenario: The Role of Perioperative Chemotherapy.- Management of Bladder Cancer with Pelvic Nodal Metastases After Complete Response to Chemotherapy.- Guideline based management muscle-invasive bladder cancer: NCCN, ICUD and EAU.

Badrinath R. Konety, MD, MBA, FACS

Professor and Chair, Dept. of Urology

Dougherty Family Chair in Urologic Oncology

Associate Director for Clinical Affairs, Masonic Cancer Center

University of Minnesota

MMC 394, 420 Delaware St

Minneapolis MN 55455, USA

 

Sam S. Chang, MD, FACS

Professor of Urologic Surgery

Patricia and Rodes Hart Chair of Urologic Surgery

Department of Urologic Surgery

Vanderbilt University Medical Center

MCN A 1302, VUMC

Nashville, TN 37232, USA

Authored by experts in their respective fields Provides a single, comprehensive reference source Useful resource for physicians Includes supplementary material: sn.pub/extras

Date de parution :

Ouvrage de 479 p.

17.8x25.4 cm

Disponible chez l'éditeur (délai d'approvisionnement : 15 jours).

137,14 €

Ajouter au panier

Ouvrage de 479 p.

17.8x25.4 cm

Sous réserve de disponibilité chez l'éditeur.

105,49 €

Ajouter au panier